These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 10836763)

  • 21. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
    AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature.
    Anderson AM; Bartlett JA
    Curr HIV/AIDS Rep; 2006 Jul; 3(2):79-85. PubMed ID: 16608664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads.
    Hauber I; Harrer T; Löw P; Schmitt M; Schwingel E; Hauber J
    AIDS; 2000 Nov; 14(16):2619-21. PubMed ID: 11101080
    [No Abstract]   [Full Text] [Related]  

  • 24. Higher antiviral activity of antiretroviral regimens including protease inhibitors.
    de Mendoza C; Soriano V; Rodríguez-Rosado R; González-Lahoz J
    AIDS; 1999 May; 13(8):998-9. PubMed ID: 10371186
    [No Abstract]   [Full Text] [Related]  

  • 25. Viral replication under combination antiretroviral therapy: a comparison of four different regimens.
    Ghani AC; Ferguson NM; Fraser C; Donnelly CA; Danner S; Reiss P; Lange J; Goudsmit J; Anderson RM; De Wolf F
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):167-76. PubMed ID: 12045679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
    Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
    AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
    [No Abstract]   [Full Text] [Related]  

  • 27. Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000.
    Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children.
    HIV Clin Trials; 2000; 1(3):58-99. PubMed ID: 11590506
    [No Abstract]   [Full Text] [Related]  

  • 28. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.
    Le Moing V; Chêne G; Carrieri MP; Alioum A; Brun-Vézinet F; Piroth L; Cassuto JP; Moatti JP; Raffi F; Leport C;
    AIDS; 2002 Jan; 16(1):21-9. PubMed ID: 11741159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
    Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
    AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral therapy in the year 2000.
    Tashima KT; Flanigan TP
    Infect Dis Clin North Am; 2000 Dec; 14(4):827-49. PubMed ID: 11144641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 34. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
    Vavro CL; Zimmermann AM; McClernon DR; Kehne SL; Martel LA; Valentine ME; McKinney RE
    Ann N Y Acad Sci; 2000 Nov; 918():381-5. PubMed ID: 11131731
    [No Abstract]   [Full Text] [Related]  

  • 36. Determinants of virological response to antiretroviral therapy: implications for long-term strategies.
    Deeks SG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S177-84. PubMed ID: 10860903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens.
    Ripamonti D; Arici C; Maggiolo F; Finazzi MG; Suter F
    AIDS; 2002 Jan; 16(1):130-1. PubMed ID: 11741174
    [No Abstract]   [Full Text] [Related]  

  • 38. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks.
    Rey D; Schmitt MP; Partisani M; Hess-Kempf G; Krantz V; de Mautort E; Bernard-Henry C; Priester M; Cheneau C; Lang JM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):459-62. PubMed ID: 11511822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
    Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focusing on the second phase of plasma HIV-1 RNA clearance.
    Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
    AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.